Skip to main content
SpringerLink
Log in

Is there a role for immunotherapy in malignant pleural mesothelioma?

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841–8.

    Article  PubMed  Google Scholar 

  2. Taioli E, van Gerwen M, Mihalopoulos M, Moskowitz G, Liu B, Flores R. Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery. J Thorac Dis. 2017;9:5423–33.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.

    Article  PubMed  CAS  Google Scholar 

  4. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed (MAPS): a randomized, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.

    Article  PubMed  CAS  Google Scholar 

  5. Baas P, Fennel D, Kerr KM, Van Schil PE, Haas RL, Petres S. Malignant pleural mesothelioma: ESMO clinical practice guidelines. Ann Oncol. 2015;26:v31-v39.

    Article  Google Scholar 

  6. Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343–73.

    Article  PubMed  Google Scholar 

  7. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21:687–92.

    Article  PubMed  CAS  Google Scholar 

  8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473–84.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.

    Article  PubMed  CAS  Google Scholar 

  11. Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171–86.

    PubMed  Google Scholar 

  12. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Ateins M, et al. First-line nivolumab in stage IV or recurrent non small cell lung cancer. N Engl J med. 2017;376:2415–26.

    Article  PubMed  CAS  Google Scholar 

  13. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non small cell lung cancer. N Engl J Med. 2016;375:1823–33.

    Article  PubMed  CAS  Google Scholar 

  14. Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161-172.

    Article  Google Scholar 

  15. Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, et al. Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J Thorac Oncol. 2018;13:124–33.

    Article  PubMed  Google Scholar 

  16. Calabrò L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single arm, phase 2 trial. Lancet Oncol. 2013;14:1104–11.

    Article  PubMed  CAS  Google Scholar 

  17. Calabrò L, Morra A, Fosatti F, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma. An open-label, single arm, phase 2 study. Lancet Respir Med. 2015;3:301–9.

    Article  PubMed  CAS  Google Scholar 

  18. Maio M, Scherpereel A, Calabrò L, Aerts J, Cedres Perez S, Bears A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicenter, international, randomized, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261–73.

    Article  PubMed  CAS  Google Scholar 

  19. Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623–30.

    Article  PubMed  CAS  Google Scholar 

  20. Kindler H, Karrison T, Carol Tan YH, Rose B, Ahmad M, Straus C, Sargis R, Seiwert T. Phase II trial of pembrolizumab in patients with malignant mesothelioma: interim analysis. J Thorac Oncol. 2017;12:S293. abstract OA13.02.

    Article  Google Scholar 

  21. Mauti L, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, et al. Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM)- outcomes in real-life setting in Australia (AUS) and Switzerland (CH). Ann Oncol. 2017;28(suppl 11):xi6-xi29.

    Google Scholar 

  22. Quispel-Janssen J, Zago G, Schouten R, Buikhulsen W, Monkhorst K, Thunissen E, Bass P. A Phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies. J Thorac Oncol. 2017;12:S292. abstract OA13.01.

    Article  Google Scholar 

  23. Goto Y, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, et al. A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT). J Thorac Oncol. 2017;12:S1883. abstract MA 19.01.

    Article  Google Scholar 

  24. Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen F, et al. Avelumab in patients with previously treated mesothelioma: updated phase Ib results from the JAVELIN solid tumor trial. J Clin Oncol 2018;36: Suppl 5S abstr 166.

  25. Zalcman G, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al. Second or 3rd line nivolumab (NIVO) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol. 2017;28(suppl 5):648. (LBA58 PR).

    Google Scholar 

  26. Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study. J Clin Oncol. 2017;35:abstr8558.

    Article  Google Scholar 

  27. Disselhorst M, Harms E, Van Tinteren H, Quispel-Janssen J, Monkhorst K, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study. J Thorac Oncol. 2017;12:S1746. abstract OA 02.02.

    Article  Google Scholar 

  28. Calabrò L, Rossi G, Maio M. New horizons from immunotherapy in malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S322-S332.

    PubMed  PubMed Central  Google Scholar 

  29. Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41:27–34.

    Article  PubMed  CAS  Google Scholar 

  30. Baldo P, Cecco S. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337–53.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20:5927–36.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Kindler HL, Novello S, Fennell DA, Blumenschein G, Bearz A, Ceresoli G, et al. Randomized phase II study of anetumab ravtansine or vinorelbine in patients with malignant pleural mesothelioma. J Thorac Oncol. 2017;12(Suppl 2):S1746. (Abstract OA 02.01).

    Article  Google Scholar 

  33. O’Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cell as anticancer therapy. Immunotherapy. 2016;8:449–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Klampatsa A, Haas AR, Moon EK, Albelda SM. Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM). Cancers 2017;9:115.

    Article  PubMed Central  Google Scholar 

  35. Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, et al. CAR-T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. 2017;6:e1363137.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Onco-Hematology, Unit of Medical Oncology, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy

    Alfredo Tartarone & Michele Aieta

  2. Hospital Pharmacy, IRCCS-CROB Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy

    Rosa Lerose

Authors
  1. Alfredo Tartarone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rosa Lerose
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Aieta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfredo Tartarone.

Ethics declarations

Conflict of interest

All the authors declared that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tartarone, A., Lerose, R. & Aieta, M. Is there a role for immunotherapy in malignant pleural mesothelioma?. Med Oncol 35, 98 (2018). https://doi.org/10.1007/s12032-018-1156-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-018-1156-x

Keywords

Search

Navigation